Get the Stockscreener App
3.25
2.20%
0.07
After Hours:
3.25
Rezolute Inc stock is traded at $3.25, with a volume of 5.55M.
It is up +2.20% in the last 24 hours and down -1.22% over the past month.
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.
See More
Previous Close:
$3.18
Open:
$3.16
24h Volume:
5.55M
Relative Volume:
1.37
Market Cap:
$311.02M
Revenue:
-
Net Income/Loss:
$-84.23M
P/E Ratio:
-3.5185
EPS:
-0.9237
Net Cash Flow:
$-77.15M
1W Performance:
+31.58%
1M Performance:
-1.22%
6M Performance:
-65.20%
1Y Performance:
+19.05%
1-Day Range:
$3.14
$3.45
1-Week Range:
$2.365
$3.66
52-Week Range:
$1.07
$11.46
Rezolute Inc Stock (RZLT) Company Profile
Name
Rezolute Inc
Sector
Industry
Phone
650-206-4507
Address
275 SHORELINE DRIVE, SUITE 500, REDWOOD CITY
Compare RZLT vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RZLT
Rezolute Inc
|
3.25 | 304.32M | 0 | -84.23M | -77.15M | -0.9237 |
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.73 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.83 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.60 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Rezolute Inc Stock (RZLT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-11-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-11-25 | Downgrade | Craig Hallum | Buy → Hold |
| Dec-11-25 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-05-24 | Initiated | Wedbush | Outperform |
| Aug-27-24 | Initiated | Guggenheim | Buy |
| Jul-17-24 | Initiated | BTIG Research | Buy |
| Jun-04-24 | Initiated | Craig Hallum | Buy |
| Apr-09-24 | Initiated | Maxim Group | Buy |
| Aug-02-22 | Resumed | Canaccord Genuity | Buy |
| Jun-15-22 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-08-21 | Initiated | ROTH Capital | Buy |
| May-27-21 | Initiated | Oppenheimer | Outperform |
| May-25-21 | Initiated | H.C. Wainwright | Buy |
View All
Rezolute Inc Stock (RZLT) Latest News
Vanguard realigns reporting; no beneficial stake in Rezolute (RZLT) - Stock Titan
Rezolute (RZLT) Gains Upgrade Following Positive FDA Meeting - GuruFocus
Cantor Fitzgerald Maintains Rezolute(RZLT.US) With Hold Rating - Moomoo
Rezolute Shares Rise After FDA Signals Hope for Treatment Approval - timothysykes.com
Rezolute Stock Gains After FDA Meeting on Ersodetug Program Update - The Globe and Mail
Rezolute’s Shares Soar Despite Initial Obstacles in Trial Data - StocksToTrade
Wedbush upgrades Rezolute stock rating on FDA feedback By Investing.com - Investing.com Australia
RZLT: Wedbush Upgrades Rezolute with Raised Price Target | RZLT Stock News - GuruFocus
Rezolute (NASDAQ:RZLT) Stock Rating Upgraded by Wedbush - MarketBeat
Cantor Fitzgerald reiterates Neutral on Rezolute stock after FDA meeting - Investing.com
Rezolute stock maintained at Buy by H.C. Wainwright after FDA meeting - Investing.com Canada
Wedbush Upgrades Rezolute to Outperform From Neutral, Raises Price Target to $5 From $2 - marketscreener.com
Citizens reiterates Market Perform on Rezolute stock after FDA update - Investing.com
FDA Review Puts Rezolute's Genetic Disorder Drug Path In Question - Sahm
Energy Moves: Is Rezolute Inc a top pick in the sectorMarket Movement Recap & Weekly Consistent Profit Watchlists - baoquankhu1.vn
BTIG reiterates Buy on Rezolute stock, keeps $5 target after FDA update - Investing.com India
Rezolute Shares Rise Following FDA Discussion Regarding Ersodetug Program Progress - Bitget
Rezolute Lauds ‘Unusual’ FDA Feedback Supportive of Path Forward for Hypoglycemia Drug - BioSpace
Rezolute Updates on Congenital Hyperinsulinism Program After FDA Meeting; SunRIZE Data Under Review for Potential Advancement 1 - Minichart
Rezolute (RZLT) Shares Surge After Positive FDA Meeting - GuruFocus
Rezolute gains after positive FDA meeting (RZLT:NASDAQ) - Seeking Alpha
Rezolute to submit sunRIZE trial data to FDA for review By Investing.com - Investing.com Canada
Rezolute (RZLT) Discusses sunRIZE Study Results with FDA - GuruFocus
Rezolute Prepares FDA Submission After sunRIZE Trial Review - TipRanks
Rezolute Says It Had Encouraging FDA Meeting on Congenital Hyperinsulinism Drug Despite Missed Endpoint - marketscreener.com
Rezolute says FDA invited submission of sunRIZE data after Type B meeting; review could inform marketing path - TradingView
Rezolute to submit sunRIZE trial data to FDA for review - Investing.com
Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting - Bitget
Rezolute, Inc.(NasdaqCM: RZLT) dropped from S&P Biotechnology Select Industry Index - marketscreener.com
Rezolute, Inc. (NASDAQ:RZLT) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Sell Signal: Can Rezolute Inc sustain earnings growth2026 Pullbacks & Free Daily Entry Point Trade Alerts - baoquankhu1.vn
Rezolute, Inc.: Fundamental Analysis and Financial Ratings | 6HV1 | US76200L3096 - marketscreener.com
RZLT Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Forecast Cut: Will Rezolute Inc outperform during market ralliesEntry Point & Growth Oriented Trade Recommendations - baoquankhu1.vn
Can Rezolute Inc sustain earnings growthWeekly Investment Recap & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Rezolute Stock: FDA Fast Track Fuels 2025 Breakout - MSN
XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements - GlobeNewswire Inc.
Rezolute (RZLT) price target decreased by 61.18% to 6.25 - MSN
RZLT Investor Sentiment - Investing.com Canada
Rezolute Shares Reeling After Clinical Trial Setback - StocksToTrade
22NW LP Invests $7.71 Million in Rezolute, Inc. $RZLT - MarketBeat
Mangrove Partners IM LLC Increases Stake in Rezolute, Inc. - National Today
Mangrove Partners IM LLC Acquires 584,660 Shares of Rezolute, Inc. $RZLT - MarketBeat
Integral Health Asset Management Boosts Stake in Rezolute, Inc. - National Today
RZLT Stock Price, Quote & Chart | REZOLUTE INC (NASDAQ:RZLT) - ChartMill
Analyst Upgrade: Is Rezolute Inc stock trending bullish2026 Volume Leaders & High Yield Equity Trading Tips - baoquankhu1.vn
RZLT.O Technical Analysis & Stock Price Forecast - Intellectia AI
Aug Macro: Is Rezolute Inc a top pick in the sector2025 Short Interest & Daily Momentum Trading Reports - baoquankhu1.vn
RZLT INVESTOR ALERT: Faruqi & Faruqi, LLP Launches Investigation into Rezolute - bastillepost.com
INVESTIGATION NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute (RZLT) - Sahm
Rezolute to Participate in the Citizens Life Sciences Conference - The Manila Times
Rezolute Inc Stock (RZLT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.04%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):